Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies (AMA)

Pharmacokinetic Considerations and Dosing Strategies of Amoxicillin and Metronidazole or Azithromycin as Adjunct to Non-surgical Periodontal Therapy. A Randomized,6-month, Parallel-group, Clinical Trial.

Periodontitits is a bacteria induced inflammatory disease that destroys the supporting tissues of the tooth and leads to tooth loss. Treatment consists mainly of the mechanical cleaning of the tooth surfaces in order to remove the bacterial deposits (plaque and calculus). This procedure can reduce the level of pathogenic bacteria but it can not eradicate them. In severe cases, for the complete resolution of the disease, the elimantion of certain species of bacteria is needed. In order to achieve that, the combination of different regimens of antibiotics adjunctive to the mechanical treatment has been proposed. However, dosage and duration of antimicrobial therapy should be optimal and not excessive as issues may arise related to increased antimicrobial resistance in the population and the individual due to habitual prescription of wide-spectrum antibiotic regimens, horizontal gene transfer and genetic mutation.

In the present study, in an effort to optimize the dosage and duration of the antimicrobial regimen, we will determine the pharmacokinetics (PK) and pharmacodynamic (PD) properties of the MET-AMO combination and of AZI in Gingival Crevicular Fluid (GCF), saliva and serum in severe periodontitis patients during and after either a 3-day or a 7-day course of treatment.

Study Overview

• Status: Recruiting
• Conditions: Periodontal Diseases; Pharmacokinetics; Antibiotics
• Intervention / Treatment: Drug: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days; Drug: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days; Drug: 1/d 500 mg Azithromycine Pfizer for 3 days

Detailed Description

This is a randomized, 3-arm parallel group, single-blind, comparative superiority and exploratory clinical trial of 44 months involving 45 patients with periodontitis attending the Division of Regenarative Dental Medecine and Periodontology of the University of Geneva. First, a routine clinical and radiographic periodontal examination will be conducted by a periodontist. Treatment will be done in 2 appointments by mechanical debridement of the diseased sites by two experienced clinicians. At the end of the treatment, one third of the patients will be assigned for treatment with 500mgAMO+ 500mgMET 3 times a day during 1 week, one third for treatment with 500mgAMO+ 500mgMET 3 times a day during 3 days and the last third for treatment with 500mg AZI once a day for 3 days.

Clinical samples will be taken at Days 0, 2, 4 and 8 after the start of the antibiotic administration . Gingival Crevicular Fluid (GCF) will be collected from four sites with paperpoints, blood sample by finger puncture, unstimulated saliva and subgingival plaque from four sites with paper points. The concentration and duration effect of AMO+MET and AZI in GCF, saliva and serum will be assessed in the Laboratory of Clinical Pharmacology at the University Hospital of Lausanne (CHUV) by high performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The microbiological effect on 6 selected organisms will be assessed by RT-PCR at 3 and 6 months after treatment. The clinical results will be evaluated 6 months later. The study duration for the patient will be approximately 8 months.

All adverse events (AE) and all serious adverse events (SAEs) will be recorded and addressed.

• Study Type: Interventional
• Enrollment (Anticipated): 45
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Catherine Giannopoulou, Dr med dent; Phone Number: 0041223794068; Email: ekaterini.giannopoulou@unige.ch
• Study Contact Backup: Name: Alkisti Zekeridou, Dr med dent; Phone Number: 0041223794031; Email: alkisti.zekeridou@unige.ch

Study Locations

• Switzerland
  • Geneva, Switzerland, 1205
    • Recruiting
    • University of Geneva, University Clinics of Dental Medicine
    • Contact: Catherine Giannopoulou, Dr med dent; Phone Number: 022 379 40 68; Email: ekaterini.giannopoulou@unige.ch
    • Contact: Alkisti Zekeridou, Dr med dent; Phone Number: 022 379 40 30; Email: alkisti.zekeridou@unige.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Informed Consent as documented by signature
• Aged 18-80 years old with need of periodontal treatment associated with adjunctive antibiotic therapy
• Presence of at least 30% of the teeth in the mouth with PD>6mm and BOP

Exclusion Criteria:

• Persons with systemic illnesses (uncontrolled diabetes mellitus, cancer, human immunodeficiency virus, bone metabolic diseases or disorders that compromise wound healing, radiation, or immunosuppressive therapy)
• Pregnancy or lactation
• Persons who had taken AB within the previous 2 months
• Persons who are taking nonsteroidal anti-inflammatory drugs
• Persons who have a confirmed or suspected intolerance to 5-nitroimidazole derivatives or amoxicillin or macrolides
• Previous periodontal therapy the last 1 year
• Known or suspected non-compliance, drug or alcohol abuse
• Inability to follow due to language problems, psychological disorders, dementia, etc. of the participant
• Participants not willing to attend regular dental maintenance visits and follow-up evaluations
• Participation in another study with investigational drug within the 30 days preceding and during the present study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Amoxicilline and Metronidazole for 7 days; Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 7 days Systemic antibiotics after sub gingival mechanical debridement	Drug: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days; Non-surgical periodontal therapy and radnomly administration of the antibiotics; Other Names: AMOXICILLINE Sandoz cpr pell 500 mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500 mg, Sanofi-Aventis ( Suisse) SA
Active Comparator: Amoxicilline and Metronidazole for 3 days; Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 3 days Systemic antibiotics after sub gingival mechanical debridement	Drug: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days; Non-surgical periodontal therapy and radnomly administration of the antibiotics; Other Names: AMOXICILLINE Sandoz cpr pell 500 mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500 mg, Sanofi-Aventis ( Suisse) SA
Active Comparator: Azithromycine for 3 days; Drug: AZITHROMYCIN Pfizer cpr pell 500mg, Pfizer PFE Switzerland GmbH 1/d 500mg for 3 days Systemic antibiotics after sub gingival mechanical debridement	Drug: 1/d 500 mg Azithromycine Pfizer for 3 days; Non-surgical periodontal therapy and radnomly administration of the antibiotics; Other Names: AZITHROMYCIN Pfizer cpr pell 500mg, Pfizer PFE Switzerland GmbH

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The concentration of AMO+MET and AZI in GCF, saliva and serum	The concentration of the drugs will be assessed in samples of gingival crevicular fluid, saliva and serum at days 0, 2, 4 and 8 after the start of the antibiotic administration.The concentration of the studied antibiotics in the different fluids will be expressed as ng/ml	At Day 0,2,4,8 post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Differences between the three treatment arms in the proportion of participants classed as treatment success at 6 months; defined as absence of sites with PD ≥ 5 mm and concomitant bleeding on probing.	Comparisons between groups assessed at 3 and 6 months after treatment	At Month 3 and Month 6 post-intervention
Differences between the three treatment arms in the levels of 6 organisms in subgingival plaque samples. For those bacteria with a threshold of >1000cells/ml, results will be expressed as median counts.	Comparisons between groups will be assessed at 3 and 6 months after treatment	At Month 3 and Month 6 post-intervention
Number of participant per treatment arm with adverse events as a mesure of safety.	Adverse events will be collected from the start of study treatment and until the end of the study (at 6 months evaluation)	At Day 2, Day 4 and Day 8 post-intervention
Patient's compliance will be evaluated	Compliance will be evaluated by pill count at the end of the antibiotherapy.	At Day 8 after intervention

Collaborators and Investigators

• Sponsor: University of Geneva, Switzerland
• Collaborators: University of Lausanne
• Investigators: Principal Investigator: Catherine Giannopoulou, Dr med dent, University Clinics of Dental Medicine, University of Geneva

Publications and helpful links

General Publications

• Giannopoulou C, Cionca N, Almaghlouth A, Cancela J, Courvoisier DS, Mombelli A. Systemic Biomarkers in 2-Phase Antibiotic Periodontal Treatment: A Randomized Clinical Trial. J Dent Res. 2016 Mar;95(3):349-55. doi: 10.1177/0022034515618949. Epub 2015 Nov 24.

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2021
• Primary Completion (Anticipated): March 1, 2024
• Study Completion (Anticipated): March 1, 2025

Study Registration Dates

• First Submitted: November 20, 2020
• First Submitted That Met QC Criteria: December 9, 2020
• First Posted (Actual): December 17, 2020

Study Record Updates

• Last Update Posted (Actual): November 2, 2022
• Last Update Submitted That Met QC Criteria: November 1, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Stomatognathic Diseases; Mouth Diseases; Periodontal Diseases; Anti-Infective Agents; Anti-Bacterial Agents; Antiprotozoal Agents; Antiparasitic Agents; Metronidazole; Amoxicillin; Azithromycin
• Other Study ID Numbers: BASEC 2020-01074

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No